ReAct welcomes the European Commission's initiative to develop a new strategy for the pharmaceutical sector in Europe. The proposed strategy should be seen against the background of several years of heated discussions in Brussels on how to address the increasing problem of high-priced medicines and patients’ lack of access to such medicines in a number of EU Member States.
The EU’s ambition to strengthen the current system and better prepare for and respond to public health threats will require the European Commission to start setting priorities based more on public health and public interest, and less on securing economic returns for the private sector. For antibiotics this should be done by implementing the principles of de-linkage and ensuring a fair return on public investment, guaranteeing that products are both affordable and subject to public health-driven stewardship policies. In an earlier policy brief published by ReAct, key points were outlined on public health principles that should govern any public funding spent, to secure equitable and sustainable access to new antibiotics.
In addition to its own submission to the EU Pharmaceutical Strategy, ReAct also supported a joint position paper in which eight civil society organizations jointly called upon the European Commission to improve transparency throughout the pharmaceutical sector and take a holistic approach to safeguarding public health and the environment.
Safeguarding policy making from undue industry influence
ReAct is concerned that some on-going partnerships between the EU and the pharmaceutical industry have and will undermine goals of transparency, affordability, and public health driven priority setting.
ReAct withdrew from the EU-funded IMI project DRIVE-AB in 2017 due to problems of undue industry influence and dominance in the project. While the final DRIVE-AB report acknowledged the inherent conflict of interest issues in the project, it proceeded to propose moving significant public funding towards the industry and organizations of some of its leading co-authors.
To avoid such satiation in the future, the new Pharmaceutical Strategy should set out policies that protect decision-making from undue influence and preferences of the pharmaceutical industry, while also ensuring transparency of how decisions are made and put in place clear safeguards to limit industry influence.
The new EU Pharmaceutical Strategy aims to improve access to safe and affordable medicines and support innovation in the EU pharmaceutical sector by addressing:
- The life cycle of medicines from Research & Development to authorization and patient access.
- How to put scientific and technological advances into practice.
- How to fill market gaps (e.g. new antimicrobials).
- Lessons learnt from COVID-19 on how to better prepare for future pandemics.
Finally ReAct encourages the European Commission to urgently address the global crisis in the antibiotics development by asserting more public leadership in developing new and more appropriate models for financing and innovation, and looks forward to continue the dialogue with the European Commission on shaping this important strategy to support such efforts.
The final Pharmaceutical Strategy for Europe will be published at the end of 2020
More news and opinion from 2020
- Nurse Dorce, Indonesia: Treating small patients with much love and infection prevention – a success story
- ReAct highlights during World Antimicrobial Awareness week 2020
- ReAct Asia Pacific: Winners of 2020 photography competition
- WAAW ReAct Africa: Engaging civil society and students
- WAAW in Indonesia: Focus on One Health approach to AMR
- Innovate4Health’s 32 finalist teams: For social innovations to address emerging infectious diseases!
- ReAct Open Letter: 5 key points to One Health Global Leaders Group on Antimicrobial Resistance
- New ReAct Report: Treatment of newborn sepsis is threatened – effective antibiotics essential
- Upcoming ReAct Africa Conference: What is the status of the NAPs on AMR in the African region?
- Animal welfare and antibiotic resistance in food animals
- ReAct activities for World Antimicrobial Awareness Week 2020
- Dr. Honar Cherif: My patients can recieve 5-10 courses of antibiotics during their cancer treatment
- New ReAct Report: Antibiotic resistance affects men and women differently
- ReAct Asia Pacific: Photo competition for students – health in focus
- 4 take aways from WHO’s first global report on sepsis
- Launch of global student design sprint – Innovate4Health
- World Sepsis Day – antibiotics essential in treatment of sepsis
- The new Pharmaceutical Strategy for Europe – an opportunity to put public interest first
- 4 key reflections on the recently launched WHO GLASS-report
- Key points from ReAct’s comments to the Independent Panel on Evidence
- ReAct Interview: From zoologist to community engagement on AMR
- ReAct Africa expands
- COVID-19 resolution – a missed opportunity to address global pandemic response more broadly
- What everyone needs to know about clinical research
- New ReAct Policy Brief: Successful cancer treatment relies on effective antibiotics
- Impact of COVID-19 on vaccine-preventable diseases and antibiotic resistance
- ReAct Africa and Africa CDC: COVID-19 webinars
- Antibiotic pollution: India scores a global first with effluent limits
- COVID-19 and AMR – what do we know so far?
- Learning from bedaquiline in South Africa – comprehensive health systems for new antibiotics
- ReAct Interview: How does antibiotics in food animal production end up in the environment?
- Key take aways from CSO workshop on AMR in Kenya
- New fact sheet: Effective antibiotics – essential for childrens’ survival
- Shortages and AMR – why should we care? 4 consequences of antibiotic shortages
- Our microbiome and noncommunicable diseases
- The 2020 AMR Benchmark Report – concerning findings with questionable framing
- 4 key reflections from engaging hospitals in India for antibiotic stewardship
- Teacher Gustavo Cedillo, Ecuador, teaches children about the bacterial world